Aktieanalys

Vitrolife: Slow start to the year in Q1e - ABG

ABG Sundal Collier Publicerad: 11 Apr 07:19

Q1'24 due 18 April
+1.8% organic sales growth in Q1'24e
EBITDA '24e-'26e up +1.4-1.5%

Q1'24e expectations

We expect Vitrolife to report +1.8% organic sales growth and a small margin uplift in Q1'24. We forecast 10% organic sales growth in Consumables and 9% organic growth in Technology, but another weak quarter for Genetics services, down 7% organically, primarily related to the US business, similar to recent quarters. We expect to see gradually improving sales in the Genetic services business over the coming quarters, as the y-o-y impact from the ERA and PGTA tests will ease starting in Q2'24e. In total, we forecast SEK 848.3m in sales for Q1 and EBITDA of SEK 261.8m, for a margin of 30.9%, up from 30.7% in Q1 '23.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/Vitrolife/Equity-research/2024/4/vitrolife---slow-start-to-the-year-in-q1e/

Nyheter om Vitrolife

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!